1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

31 May 2024
Admin
News Article

Fusion Pharmaceuticals Acquisition by AstraZeneca Gets Shareholder Approval

Overview

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a company in the field of oncology focusing on the development of advanced radioconjugates (RCs) as targeted therapies, made an announcement today regarding the results of a special virtual meeting of its shareholders. At this meeting, shareholders voted in favor of a proposal related to a previously disclosed plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act. This arrangement involves AstraZeneca acquiring all outstanding shares of Fusion (referred to as the "Arrangement").

Approximate Shares

As of the record date of April 16, 2024, there were approximately 84,965,608 shares outstanding and eligible to vote. A total of 68,678,602 shares were voted at the meeting, representing roughly 80.83% of the total outstanding shares.

The Approval

The Arrangement received approval, meeting the required affirmative vote percentages from both shareholders voting as a single class and shareholders excluding those whose votes are to be excluded under applicable regulations.

A detailed report on the voting outcomes for all matters discussed at the meeting will be filed on Fusion's profile on SEDAR+ at www.sedarplus.com.

Completion of the arrangement is subject to court approval and other customary closing conditions. Assuming these conditions are met, the transaction is expected to be finalized in the second quarter of 2024.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!